Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia
Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia
The objective of this study is to evaluate the efficacy of romiplostim administered once
 weekly to Aplastic Anemia (AA) patients with thrombocytopenia refractory to or ineligible for
 immunosuppressive therapy in Japan and Korea.

 Safety and pharmacokinetics of romiplostim after repeated administration will also be
 assessed.
Inclusion Criteria:

 -  Diagnosis of Aplastic Anemia (AA) confirmed by peripheral blood and bone-marrow
 examinations, etc.

 -  Refractory to at least one course of immunosuppressive therapy including horse or
 rabbit anti-human thymocyte immunoglobulin (ATG); or ineligible for ATG treatment and
 refractory to cyclosporin (CyA)

 -  Thrombocytopenia defined as a platelet count of ≤ 30 × 10^9/L

 -  Preserving main organ function as a result of screening as follows;

 -  Total bilirubin: < 1.5 times the upper limit of the laboratory normal range

 -  Alanine aminotransferase: < 3.0 times the upper limit of the laboratory normal
 range

 -  Aspartate aminotransferase: < 3.0 times the upper limit of the laboratory normal
 range

 -  Creatinine value: ≤ 2.0 mg/dL

 -  An Eastern Cooperative Oncology Group performance status score of 0 to 2 at screening

 -  ≥ 20 years of age at the time of obtaining informed consent

 -  Patients who have provided written informed consent of their free will to participate
 in this study

 Exclusion Criteria:

 -  Concurrent active infection not adequately responding to appropriate therapy

 -  Bone marrow reticulin grade of ≥ 2 based on the grading scale for reticulin indicated
 in Bone Marrow Pathology (2nd edition)

 -  Proportion of blasts in bone marrow > 2%

 -  Previous or concurrent active malignancies, other than localized tumors diagnosed more
 than one year previously and treated surgically with curative intent (basal cell
 carcinoma; or surgically resected in situ carcinoma of the cervix with an apparent
 success of ≥ 12 months prior to enrollment; as well as other cancers which have not
 been treated and remained disease-free for at least 5 years before enrollment are
 eligible)

 -  Clinically significant cardiac disease (class III or IV of the New York Heart
 Association classification; unstable angina pectoris; myocardial infarction within 6
 months before enrollment; cardiac disease accompanied by angioplasty or stenting
 within 6 months before enrollment; or clinically significant cardiac arrhythmias) or
 uncontrollable hypertension

 -  Arterial or venous thrombosis within one year before enrollment

 -  Positive for anti-human immunodeficiency virus antibodies, hepatitis B surface
 antigen, or hepatitis C virus-RNA at screening

 -  Thrombocytopenia due to any other cause (e.g., myelodysplastic syndrome, idiopathic
 thrombocytopenic purpura, or liver cirrhosis)

 -  Patients with acute myeloblastic leukemia or chronic myelomonocytic leukemia

 -  Concurrent occurrence of hemolytic predominant paroxysmal nocturnal hemoglobinuria
 (Hemolytic predominant is defined as lactate dehydrogenase > 1.5 times the upper limit
 of the laboratory normal range)

 -  Uncontrolled diabetes mellitus

 -  Receiving other investigational products within 16 weeks before romiplostim treatment
 initiation

 -  Receiving any agent to treat AA, including the following agents before romiplostim
 treatment initiation;

 -  ATG treatment within 6 months before romiplostim treatment initiation

 -  CyA or anabolic steroid treatment within 6 weeks before romiplostim treatment
 initiation:

 However, the patients who are treated with a CyA or anabolic steroid for at least 6 months
 before romiplostim treatment initiation may be enrolled if their blood cell count are
 stable at screening, and their dosage and administration will be kept for 6 weeks before
 romiplostim treatment initiation and during romiplostim dosing period.

 -  A history of polyethylene glycol-conjugated recombinant human megakaryocyte growth and
 development factor, recombinant human thrombopoietin (TPO), romiplostim, or other
 TPO-receptor agonists

 -  Having a plan to undergo hematopoietic stem cell transplantation within 1 year

 -  Having hypersensitivity to any recombinant protein E. coli derivative protein

 -  Lactating or pregnant women or women of child-bearing potential who have no intention
 of using oral contraceptives or birth control

 -  Having abnormalities by the cytogenetic test in bone marrow cells

 -  Patients who are considered to be ineligible for the study by the investigator or
 subinvestigator for reasons other than above